Overview of Oral antiviral Molnupiravir and COVID-19!

[Bruce M. Jones]

COVID-19 is not the first disease that seriously affected the human population and is caused by the coronavirus. But in the 2002–04 severe acute respiratory syndrome (SARS) epidemic and the Middle East respiratory syndrome (MERS) outbreak in 2012 were also forms of coronavirus. But since then, only a few antiviral drugs have been made to-date because drugmakers have only a little incentive to develop antiviral drugs for such diseases.
If we go back, we can see between 1963 and early 2016, only about 90 drugs were formally approved to treat 9 human diseases caused by a virus infection, including antivirals against HIV (Human Immunodeficiency Virus), HBV (Hepatitis B Virus), HCV (Hepatitis C Virus), HSV (Herpes Simplex Viruses), HCMV (Human Cytomegalovirus), HPV (Human Papillomavirus), RSV (Respiratory Syncytial Virus), VZV (Varicella-Zoster Virus), and the Influenza virus. So, the approval of Molnupiravir would be a remarkable achievement and a great benefit to COVID-19 patients, as this is the first oral antiviral drug for such viral diseases. U.K.’s Medicines and Healthcare Products Regulatory Agency Authorizes Molnupiravir for the Treatment of Mild-to-Moderate COVID-19 in Adults with a Positive SARS-CoV-2 Diagnostic Test and Who Have at Least One Risk Factor for Developing Severe illness.

[BradleyTJones]

I am still doing my research on COVID-19 and thanks for little help.